Abstract
The Peroxisome Proliferator-Activated Receptors-PPARα, PPARγ, and PPARδ--are members of the nuclear receptor gene family that have emerged as therapeutic targets for the development of drugs to treat human metabolic diseases. The discovery of high affinity, subtype-selective agonists for each of the three PPAR subtypes has allowed elucidation of the pharmacology of these receptors and development of first-generation therapeutic agents for the treatment of diabetes and dyslipidemia. However, despite proven therapeutic benefits of selective PPAR agonists, safety concerns and dose-limiting side effects have been observed, and a number of late-stage development failures have been reported. Scientists have continued to explore ligand-based activation of PPARs in hopes of developing safer and more effective drugs. This review highlights recent efforts on two newer approaches, the simultaneous activation of all three PPAR receptors with a single ligand (PPAR pan agonists) and the selective modulation of a single PPAR receptor in a cell or tissue specific manner (selective PPAR modulator or SPPARM) in order to induce a subset of target genes and affect a restricted number of metabolic pathways.
Keywords: PPAR pan agonist, PPAR modulator, SPPARM, PPARγ, metabolic disease, diabetes, coregulator
Current Topics in Medicinal Chemistry
Title: PPAR Modulators and PPAR Pan Agonists for Metabolic Diseases: The Next Generation of Drugs Targeting Peroxisome Proliferator-Activated Receptors?
Volume: 8 Issue: 9
Author(s): P. L. Feldman, M. H. Lambert and B. R. Henke
Affiliation:
Keywords: PPAR pan agonist, PPAR modulator, SPPARM, PPARγ, metabolic disease, diabetes, coregulator
Abstract: The Peroxisome Proliferator-Activated Receptors-PPARα, PPARγ, and PPARδ--are members of the nuclear receptor gene family that have emerged as therapeutic targets for the development of drugs to treat human metabolic diseases. The discovery of high affinity, subtype-selective agonists for each of the three PPAR subtypes has allowed elucidation of the pharmacology of these receptors and development of first-generation therapeutic agents for the treatment of diabetes and dyslipidemia. However, despite proven therapeutic benefits of selective PPAR agonists, safety concerns and dose-limiting side effects have been observed, and a number of late-stage development failures have been reported. Scientists have continued to explore ligand-based activation of PPARs in hopes of developing safer and more effective drugs. This review highlights recent efforts on two newer approaches, the simultaneous activation of all three PPAR receptors with a single ligand (PPAR pan agonists) and the selective modulation of a single PPAR receptor in a cell or tissue specific manner (selective PPAR modulator or SPPARM) in order to induce a subset of target genes and affect a restricted number of metabolic pathways.
Export Options
About this article
Cite this article as:
Feldman L. P., Lambert H. M. and Henke R. B., PPAR Modulators and PPAR Pan Agonists for Metabolic Diseases: The Next Generation of Drugs Targeting Peroxisome Proliferator-Activated Receptors?, Current Topics in Medicinal Chemistry 2008; 8 (9) . https://dx.doi.org/10.2174/156802608784535084
DOI https://dx.doi.org/10.2174/156802608784535084 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondria: the Headquarters in Ischemia-Induced Neuronal Death
Central Nervous System Agents in Medicinal Chemistry Synthesis, Structural Determination of a New Ocotillol Derivative and its Epimer
Letters in Organic Chemistry Soluble Amyloid-β Levels and Late-Life Depression
Current Pharmaceutical Design Complications of Anti-Vascular Endothelial Growth Factor Drugs
Current Drug Therapy New Advances in the Field of Calcium Channel Antagonists: Cardiovascular Effects and Structure-Activity Relationships
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Elevated Serum Human Cytomegalovirus IgM Levels in the Acute Phase of Ischemic Stroke are Associated with Increased Risk of Death and Major Disability
Current Neurovascular Research Anti-apoptotic Serpins as Therapeutics in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Recent Patents on Biomedical Applications for the Treatment of Atherosclerosis
Recent Patents on Regenerative Medicine Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy The Role of Calcium and the L-Type Calcium Channel in Pathological Remodeling of the Heart
Vascular Disease Prevention (Discontinued) Cell Therapy for Stroke: Emphasis on Optimizing Safety and Efficacy Profile of Endothelial Progenitor Cells
Current Pharmaceutical Design The Role of Vascular Factors in Late-Onset Sporadic Alzheimers Disease. Genetic and Molecular Aspects
Current Alzheimer Research A1 Receptors Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Potential Targets for Anti-Inflammatory and Anti-Allergic Activities of Marine Algae: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Postoperative Care of the Transplanted Patient
Current Cardiology Reviews Cardioprotective Effects of Natural Products <i>via</i> the Nrf2 Signaling Pathway
Current Vascular Pharmacology Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design Exercise and Ischemic Preconditioning
Current Cardiology Reviews Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design